스위스 - 이탈리아어 - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - teriflunomidum - compresse rivestite con film - comprimé pelliculé: teriflunomidum 14 mg, color.: e 132, excipiens pro compresso obducto. - traitement des patients adultes et des patients pédiatriques de 10 ans et plus présentant des formes récurrentes-rémittentes de sclérose en plaques (sep) - synthetika

스위스 - 이탈리아어 - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - natalizumabum - injektionslösung in einer fertigspritze - natalizumabum 150 mg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas heptahydricus, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 3.45 mg. - multiple sklerose - biotechnologika

유럽 연합 - 이탈리아어 - EMA (European Medicines Agency)

mylan ireland limited - dimetilfumarato - sclerosi multipla recidivante-remittente - immunosoppressori - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

유럽 연합 - 이탈리아어 - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetilfumarato - sclerosi multipla recidivante-remittente - immunosoppressori - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

유럽 연합 - 이탈리아어 - EMA (European Medicines Agency)

teva gmbh - dimetilfumarato - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressori - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

유럽 연합 - 이탈리아어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - dimetilfumarato - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressori - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

유럽 연합 - 이탈리아어 - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressori - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

이탈리아 - 이탈리아어 - AIFA (Agenzia Italiana del Farmaco)

piramal critical care italia s.p.a. - dimethyl fumarate - dimethyl fumarate

이탈리아 - 이탈리아어 - AIFA (Agenzia Italiana del Farmaco)

adalvo limited - dimethyl fumarate - dimethyl fumarate